CD4
1 T cells play a pivotal role in adaptive immunity, because they are required for the development and maintenance of memory and cytotoxic CD8 1 T cells [1] [2] [3] [4] . On the other hand, human immunodeficiency virus (HIV)-specific CD4 1 T cells serve as the primary target cell population for viral replication [5] . Thus, induction of HIV-specific CD4 1 T cells may have pleiotropic effects, on the one hand protecting against HIV through its role in adaptive immune responses but, at the same time, generating a pool of target cells for HIV propagation. HLA class II molecules are involved in presenting antigen to CD4 1 T cells, and their role is therefore considered central for the development and maintenance of HIV-specific CD4 1 T-helper cells. Of the 10 genes that encode for HLA class II molecules (reported as of January 2010), the DRB1 gene at the DRB locus is the most diverse, encoding for 762 distinct alleles (http://hla.alleles.org/nomenclature/stats.html).
Despite the potential role of HLA class II alleles in HIV infection, only a limited number of alleles have been associated with HIV disease outcome [6] [7] [8] [9] [10] [11] [12] . In particular, several DRB1*13 alleles and the DRB1*13-DQB1*06 haplotype have been reported to confer a certain degree of protection, but all of these reports focused on highly selected patient subsets, including long-term nonprogressors, subjects treated during acute infection, and children with vertically transmitted HIV. The role of HLA class II alleles in chronic progressive HIV infection remains unknown.
To investigate the effect of HLA class II alleles on disease progression in chronic HIV infection, we studied a wellcharacterized cohort of 426 antiretroviral therapy (ART)-naive, HIV-1 clade C-infected, mainly female black South Africans, as well as 1436 HIV-1 clade B virus-infected persons from the Multicenter AIDS Cohort Study (MACS). Here we report that the DRB1*1303 allele is associated with reduced viral loads (VLs) in both B and C clade populations, although DRB1*1303 expression was not associated with an increased frequency of interferon (IFN) c-positive HIV-specific CD4
1 T cell responses.
This suggests that the protective activity of specific HLA class II alleles may be mediated via an alternative mechanism.
MATERIALS AND METHODS

Ethics Statement
For the Sinikithemba cohort, written consent was obtained from all study participants. We also analyzed 1436 HIV-1-infected male white subjects from the MACS, a prospective, observational study of natural histories of HIV-1 infection in the United States [13] . HLA class I and DRB1 typing, as well as mean CD4 For DRB1 sequence-based typing, generic DR types were first elucidated by sequence-specific PCR followed by group-specific PCR amplification and sequencing of exon 2. Sequencing results were interpreted with the help of the ASSIGN 3.5 software developed by Conexio Genomics. Ambiguities were resolved by using allele-specific PCR primers to isolate each of the 2 alleles in heterozygous individuals.
Intracellular Cytokine Staining
The intracellular cytokine assay was conducted using peripheral blood mononuclear cells isolated from whole blood within 4 h of phlebotomy, as described elsewhere [14] . From the Sinikithemba cohort, 403 patients were screened for CD4 1 and CD8 1 T lymphocyte responses against a peptide pool spanning the HIV-1 protein Gag; 318 were also screened for responses against the proteins Pol, Env, Nef, Acc, and Reg (based on HIV-1 clade C consensus sequence 2001). Control conditions were established by using 2 tubes of unstimulated peripheral blood mononuclear cells per patient (with the average background subtracted from the response for the experimental tubes). A response was considered positive for HIV-1-specific T cells if it was still greater than the background after subtraction of the average background. Gag specific CD4 1 T cell responses as well as HIV-specific CD8 1 T cell responses from a subset of the Sinikithemba cohort have been reported elsewhere [15, 16] .
Statistical Analysis
SAS software (version 9.1; SAS Institute) was used for statistical analyses, and graphs were plotted using GraphPad Prism software (version 4). The VLs were transformed into log scale, and the CD4 1 T cell counts are shown as square roots to account for normal distribution. Procedure PROC GLM was used for analysis of variance, and Bonferroni correction was performed for multiple comparisons. To eliminate confounding by the effect of HLA B*57 in the Sinikithemba cohort, this factor was used as a covariate in the analysis; both HLA B*27 and HLA B*57 were used as covariates in the analysis of the MACS cohort.
Further analysis with adjustment for sex or age did not change the overall results (data not shown). T cell responses were compared using the Mann-Whitney test. Survival analysis was performed using the Cox proportional hazard model.
RESULTS
Frequencies of HLA Class II Molecules in HIV-1 Clade C-Infected Zulu/Xhosa from South Africa
We first determined allele frequencies at the DRB1 and DQB1 loci (n 5 426 for DRB1, n 5 385 for DQB1) in a cohort of chronically HIV-1-infected, untreated Zulu/Xhosa subjects (Sinikithemba cohort) in KwaZulu Natal Province, South Africa, where the overall seroprevalence rates are among the highest on the African continent (UNAIDS 2008; http://data. unaids.org/pub/Report/2008/20080904_southafrica_anc_2008_ en.pdf). DRB1*0302 was the most common DRB1 allele observed (n 5 140; 16.43%) followed by DRB1*1101 (n 5 115; 13.50%) and DRB1*1301 (n 5 101; 11.85%), whereas DRB1*1303 was expressed in only 1.9% (n 5 16) of the population. In African Americans, DRB1*1303 has been reported to be expressed at slightly higher rates (3.5%-3.7% of individuals (http://www.allelefrequencies.net), compared with 1% of European Americans). Allele frequencies for HIV-uninfected black South Africans are not available. In the Sinikithemba cohort, DQB1*06 was the most common DQB1 allelic group expressed (n 5 249; 32.4%), followed by DQB1*03 (n 5 159; 20.56%), DQB1*04 (n 5 143; 18.57%), and DQB1*02 (n 5 134; 17.40%). 1993, and death, hazard ratios ranged from .54 to .67), although this was not significant. Because HLA B*57 and DRB1*1303 are in linkage disequilibrium in African populations, we tested whether DRB1*1303 confers protection in the absence of B*57. Half of the Sinikithemba samples (8/16) but only 1 of 30 MACS samples carried both DRB1*1303 and HLA-B*57. The 8 subjects who were carriers of DRB1*1303 but not B*57 had a mean plasma VL of 4.15 log 10 HIV RNA copies/mL, compared with 4.65 log 10 HIV RNA copies/mL for the DRB1*1303 noncarriers (P 5 .13). Although the difference in VL was not significant, the trend was consistent with protection. As expected, DRB1*1303 in the absence of B*57 was significantly associated with lower VLs (P 5 .02) and higher CD4 1 T cell counts (P 5 .03) after excluding the single carrier of both DRB1*1303 and B*57 from the analysis. Given the well-described protection conferred by HLA B*57 [17] , we attempted to determine in the Sinikithemba cohort whether DRB1*1303 enhances HLA B*57 protection. We compared the mean VL of individuals expressing HLA B*57 plus DRB1*1303 with that of individuals expressing HLA B*57 but not DRB1*1303. Interestingly, subjects with both HLA B*57 and DRB1*1303 expression had a lower mean VL than those who expressed HLA B*57 but not DRB1*1303, though this difference did not reach significance (mean log 10 plasma VL, 3.7 vs 4.36 HIV RNA copies/mL, respectively; P 5 .11). Thus, DRB1*1303 may enhance the protective effect of HLA B*57, potentially through a mechanism mediated by CD4 1 T-helper cells, but further studies are necessary to confirm or negate this hypothesis. (Figure 2A ). Although we did observe a trend toward lower total HIV-specific CD4 1 T cell counts in the DRB1*1303 carriers (.23% vs .42% of total CD4 1 T cells; P 5 .09) ( Figure   2B ), this trend was driven by the Gag responses, because total HIV responses excluding Gag (ie, Pol, Env, Nef, Acc, and Reg only) showed no significant difference between the DRB1*1303 carriers and noncarriers (data not shown). In contrast, no significant differences were observed between DRB1*1303 carriers and noncarriers in Gag-specific (.86% vs .84%; P 5 .99) or total (3.11% vs 3.96%; P 5 .23) CD8 1 T cell responses ( Figure 3A and B). Adjustment of T cell responses for mean VLs had no influence on the results (data not shown), suggesting that lower Gag-specific CD4 1 T cell counts in DRB1*1303 carriers are not a consequence of antigen exposure. Rather, reduction of the Gag-specific CD4 1 T cell population, which accounts for 40% of the total HIV-specific CD4 1 T cell pool, might contribute to reducing VLs by limiting the number of target cells available for HIV to infect.
DISCUSSION
There is strong evidence for the association between HLA class I alleles and HIV disease outcome [16] [17] [18] [19] , but the role of HLA class II alleles in chronic HIV-1 infection has not yet been examined in such detail. Because HLA class II molecules determine the antigen specificity of CD4 1 T cells, they might be indirectly involved in the control of HIV infection; HIV-specific CD4
1
T-helper cells are required for the development of memory and cytotoxic CD8 1 T cells [1] [2] [3] [4] .
To understand better the interaction between HLA class II alleles, HIV disease outcome, and HIV-specific CD4
1 T cell responses, we examined 426 subjects in the Sinikithemba cohort, consisting of ART-naive, HIV-1 clade C-infected, predominantly female black South Africans. We hypothesized that certain HLA class II alleles are associated with reduced VLs in chronic HIV-1 clade C infection, as has been shown for several HLA B-alleles in this same cohort [16] . Individuals expressing the DRB1*1303 allele showed significantly lower mean plasma VLs compared with the rest of the cohort, even after correction for the protective HLA class I allele B*57, which is in linkage disequilibrium with DRB1*1303 in populations of African descent. Furthermore, an analysis of the DRB1*1303 allele in 1436 chronically HIV B clade-infected, untreated white male subjects from the MACS cohort in the United States also revealed that carriers of the DRB1*1303 allele had significantly lower VLs and increased CD4 1 T cell counts, thus supporting our initial observation of a moderate protective effect of this allele. Our data suggest that the effect of DRB1*1303 on mean plasma VLs is mediated independently of ethnic background or infecting HIV-1 clade. Additionally the effect of DRB1*1303 appears to be independent of sex as well, because .80% of subjects in the African cohort were female, but the MACS cohort was entirely male. The observation that DRB1*13 confers protection has been shown in other infections, in particular hepatitis B virus infection, where this allele is associated with a higher frequency of clearance and/or better clinical disease course [20] [21] [22] [23] [24] . Furthermore, studies in human papillomavirus (HPV) infection have associated DRB1*13 with protection against the HPV-16 serotype, and DRB1*13 was negatively correlated with the occurrence of cervical carcinoma [25, 26] . In contrast, DRB1*13 enrichment has also been reported in subjects with autoimmune diseases, including anti-citrullinated protein antibody-negative rheumatoid arthritis [27] , severe forms of Henoch-Schönlein purpura [28] , and type 1 autoimmune hepatitis [29] . DRB1*1303 might therefore share some similarities with the HLA class I allele B*2705, which is associated with protection in HIV and HCV infection [16, 17, 30] but is common among patients with autoimmune disorders, such as ankylosing spondyloarthritis [31] . It has been proposed that the effect of DRB*13 on disease pathogenesis may be related to particularly effective antigen presentation capacity, which confers protection against viral infections, but may trigger autoimmunity through molecular mimicry with self-antigens [32] . It remains uncertain, however, whether the observed associations can be attributed to a stronger and more effective T cell response or whether other mechanisms mediate the DRB1*13 effect.
Because increased frequencies of HIV-specific CD4 
